Pacer Advisors, Inc. Viking Therapeutics, Inc. Transaction History

Pacer Advisors, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$47.39 - $80.2 $62,412 - $105,623	1,317 Added 222.47%	1,909 $101,000
Q1 2024 May 10, 2024	BUY	$17.4 - $94.5 $10,300 - $55,944	592 New	592 $48,000
Q2 2021 Jul 21, 2021	SELL	$5.19 - $6.73 $42,246 - $54,782	-8,140 Closed	0 $0
Q1 2021 Apr 05, 2021	SELL	$5.74 - $9.67 $1,331 - $2,243	-232 Reduced 2.77%	8,140 $51,000
Q4 2020 Jan 20, 2021	BUY	$5.3 - $6.71 $13,764 - $17,425	2,597 Added 44.97%	8,372 $47,000
Q3 2020 Oct 19, 2020	BUY	$5.73 - $8.11 $33,090 - $46,835	5,775 New	5,775 $34,000
Q4 2018 Feb 13, 2019	SELL	$7.16 - $16.21 $135,997 - $307,892	-18,994 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$9.7 - $19.65 $184,241 - $373,232	18,994 New	18,994 $331,000

476

63.4M

5.76M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $2.5B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Pacer Advisors, Inc. with notifications on news.